This study identified both a new noninvasive imaging-based biomarker and a hematological parameter that were correlated with poor outcomes after PD-1/PD-L1 blockade plus chemotherapy in patients with advanced-stage NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.